Nuhearas Strategic Shift and Capital Boost

Nuheara Limited (ASX: NUH) embarks on a strategic overhaul to explore future growth paths, contemplating mergers and acquisitions as a key strategy. This move follows after raising $1.85 million through share placement to bolster the strategic review process. Positioned for its next evolution phase, thanks to its FDA-approved hearing aid and expanding US retail presence, Nuheara aims to enhance its sales and marketing capabilities.

The firm's focus will now shift towards finalizing new chip development and its next-gen product, with reduced investment in current product lines to limit external capital needs during this transition. Azure Capital assists in the strategic review, aiming for a return to ASX trading post-capital raise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com